###begin article-title 0
BRAF Activation Initiates but Does Not Maintain Invasive Prostate Adenocarcinoma
###end article-title 0
###begin p 1
Conceived and designed the experiments: LC. Performed the experiments: JHJ ZW ASG XO JLF ZD SJ IG ES. Analyzed the data: JHJ ZW WCH MFL CAS LC. Contributed reagents/materials/analysis tools: ASG JLF GHK WCH MFL CAS RW. Wrote the paper: JHJ LC.
###end p 1
###begin p 2
###xml 456 461 456 461 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 930 935 918 923 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 1099 1104 1087 1092 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 72 75 <span type="species:ncbi:9606">men</span>
###xml 370 375 <span type="species:ncbi:10090">mouse</span>
###xml 377 380 <span type="species:ncbi:10090">GEM</span>
###xml 502 507 <span type="species:ncbi:9606">human</span>
###xml 638 641 <span type="species:ncbi:10090">GEM</span>
###xml 642 646 <span type="species:ncbi:10090">mice</span>
Prostate cancer is the second leading cause of cancer-related deaths in men. Activation of MAP kinase signaling pathway has been implicated in advanced and androgen-independent prostate cancers, although formal genetic proof has been lacking. In the course of modeling malignant melanoma in a tyrosinase promoter transgenic system, we developed a genetically-engineered mouse (GEM) model of invasive prostate cancers, whereby an activating mutation of BRAFV600E-a mutation found in approximately10% of human prostate tumors-was targeted to the epithelial compartment of the prostate gland on the background of Ink4a/Arf deficiency. These GEM mice developed prostate gland hyperplasia with progression to rapidly growing invasive adenocarcinoma without evidence of AKT activation, providing genetic proof that activation of MAP kinase signaling is sufficient to drive prostate tumorigenesis. Importantly, genetic extinction of BRAFV600E in established prostate tumors did not lead to tumor regression, indicating that while sufficient to initiate development of invasive prostate adenocarcinoma, BRAFV600E is not required for its maintenance.
###end p 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 337 341 337 341 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTEN</italic>
###xml 343 345 343 345 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">RB</italic>
###xml 351 354 351 354 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p27</italic>
###xml 374 380 374 380 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NKX3.1</italic>
###xml 406 411 406 411 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c-Myc</italic>
###xml 420 423 420 423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003949-EllwoodYen1">[1]</xref>
###xml 425 428 425 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003949-Hill1">[2]</xref>
###xml 430 433 430 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003949-Kim1">[3]</xref>
###xml 435 438 435 438 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003949-Trotman1">[4]</xref>
###xml 440 443 440 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003949-Wang1">[5]</xref>
###xml 701 704 701 704 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003949-Kim1">[3]</xref>
###xml 706 709 706 709 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003949-Trotman1">[4]</xref>
###xml 711 714 711 714 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003949-Wang1">[5]</xref>
###xml 738 741 738 741 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003949-Mulholland1">[6]</xref>
###xml 743 746 743 746 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003949-Xin1">[7]</xref>
###xml 958 961 958 961 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003949-Wang1">[5]</xref>
###xml 963 966 963 966 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003949-AbateShen1">[8]</xref>
###xml 968 971 968 971 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003949-Bentel1">[9]</xref>
###xml 973 977 973 977 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003949-Bookstein1">[10]</xref>
###xml 979 983 979 983 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003949-Brewster1">[11]</xref>
###xml 985 989 985 989 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003949-Chen1">[12]</xref>
###xml 991 995 991 995 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003949-Navone1">[13]</xref>
###xml 997 1001 997 1001 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003949-Navone2">[14]</xref>
###xml 1003 1007 1003 1007 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003949-Stackhouse1">[15]</xref>
###xml 1009 1013 1009 1013 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003949-Theodorescu1">[16]</xref>
###xml 62 65 <span type="species:ncbi:9606">men</span>
###xml 281 286 <span type="species:ncbi:9606">human</span>
Prostate cancer (PCA) is the most common malignancy affecting men over age of 65. Initially responsive to hormonal ablation therapy, PCA invariably recur and evolve to become lethal androgen-independent (AI) disease. While a number of common genetic events have been implicated in human prostate carcinogenesis including those targeting PTEN, RB, and p27 tumor suppressors, NKX3.1 tumor modulator, and the c-Myc oncogene[1], [2], [3], [4], [5], the genetic and biological basis governing progression to invasive and metastatic or AI disease is less well understood. Extensive genetic and experimental evidence have underscored the importance of the PI3K-PTEN-AKT signaling pathway, not only in genesis[3], [4], [5] but also in progression[6], [7] of PCA. In addition, specific genetic events, such as androgen receptor mutation or amplification, Bcl2 activation, and/or loss of p53 tumor suppressor function, had been associated with transition to AI disease[5], [8], [9], [10], [11], [12], [13], [14], [15], [16].
###end p 4
###begin p 5
###xml 313 317 313 317 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003949-Gioeli1">[17]</xref>
###xml 465 473 465 473 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 473 477 473 477 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003949-Voeller1">[18]</xref>
###xml 793 797 793 797 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003949-Thomas1">[19]</xref>
###xml 896 900 896 900 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003949-Konishi1">[20]</xref>
###xml 902 906 902 906 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003949-Lin1">[21]</xref>
###xml 908 912 908 912 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003949-Sasaki1">[22]</xref>
###xml 914 918 914 918 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003949-Shiraishi1">[23]</xref>
###xml 920 924 920 924 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003949-Suzuki1">[24]</xref>
###xml 1060 1065 1060 1065 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 1085 1089 1085 1089 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003949-Cho1">[25]</xref>
###xml 1229 1233 1229 1233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003949-Gao1">[26]</xref>
###xml 1398 1402 1398 1402 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003949-Tomlins1">[27]</xref>
###xml 294 299 <span type="species:ncbi:9606">human</span>
###xml 774 779 <span type="species:ncbi:9606">human</span>
###xml 823 826 <span type="species:ncbi:9606">men</span>
###xml 962 970 <span type="species:ncbi:9606">patients</span>
###xml 1208 1213 <span type="species:ncbi:9606">human</span>
###xml 1327 1332 <span type="species:ncbi:9606">human</span>
In contrast, the role of activated RAS-RAF-MAPK signaling in PCA is less well-established, although a growing body of evidence implicates the pathogenetic relevance of this pathway in prostate cancer biology. First, MAP kinase activation has been shown to correlate with disease progression in human PCA specimens[17]. Second, virtually all AI xenografts exhibit elevated phospho-MAP kinase levels and RAS activation renders LNCaP cells less dependent on androgens in vitro[18]. Furthermore, analysis of various RAS effecter mutants with differential capacity to engage specific downstream signaling pathways has also highlighted the MAPK axis in reducing androgen-dependence of LNCaP cells. Third, activating mutations in all three RAS family members have been reported in human PCA specimens[19], primarily from Japanese men, wherein these early studies reported a 13-30% frequency of mutations[20], [21], [22], [23], [24]. More recently, in a study of Korean patients, KRAS activating mutations were detected in 7% of cases and another 10% harbored the BRAFV600E activating mutation[25]. In consonance with these mutation data, Raf1 expression is often found to be elevated and B-Raf inhibitor reduced in human prostate tumors[26]. Lastly, ETV1/ER85, a partner in the high frequency TMPRSS2:ETV1 chromosomal fusion event in human prostate cancer, is a downstream target of RAS-RAF-MAPK signaling[27]. These reinforcing, albeit correlative, data have implicated activated RAS-RAF-MAPK signaling in the prostate cancer genesis and progression.
###end p 5
###begin p 6
###xml 178 182 178 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003949-AbateShen2">[28]</xref>
###xml 184 188 184 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003949-Kasper1">[29]</xref>
###xml 288 295 288 295 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">myr-AKT</italic>
###xml 299 303 299 303 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 337 340 337 340 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 344 347 344 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p27</italic>
###xml 360 363 360 363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003949-Kim1">[3]</xref>
###xml 365 368 365 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003949-Trotman1">[4]</xref>
###xml 370 373 370 373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003949-Wang1">[5]</xref>
###xml 375 379 375 379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003949-Chen1">[12]</xref>
###xml 381 385 381 385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003949-DiCristofano1">[30]</xref>
###xml 387 391 387 391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003949-Gao2">[31]</xref>
###xml 393 397 393 397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003949-Majumder1">[32]</xref>
###xml 469 474 469 474 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c-Myc</italic>
###xml 492 495 492 495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003949-EllwoodYen1">[1]</xref>
###xml 497 501 497 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003949-Kasper2">[33]</xref>
###xml 503 507 503 507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003949-Zhang1">[34]</xref>
###xml 23 28 <span type="species:ncbi:10090">mouse</span>
###xml 30 33 <span type="species:ncbi:10090">GEM</span>
###xml 219 222 <span type="species:ncbi:10090">GEM</span>
###xml 478 482 <span type="species:ncbi:10633?0.9966199903428296">SV40</span>
###xml 509 512 <span type="species:ncbi:10090">GEM</span>
Genetically engineered mouse (GEM) models have enabled the validation and functional analysis of several key genetic alterations found in prostate cancer development (reviewed in[28], [29]. The majority of invasive PCA GEM models have largely emphasized AKT activation strategies such as myr-AKT or Pten deletion, alone or together with p53 or p27 inactivation[3], [4], [5], [12], [30], [31], [32]. Other well-established models include prostate-specific expression of c-Myc or SV40 oncogenes[1], [33], [34]. GEM model of invasive prostate cancers driven by MAPK activation has not been reported.
###end p 6
###begin p 7
###xml 61 64 61 64 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V12</sup>
###xml 146 149 146 149 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V12</sup>
###xml 165 174 165 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ink4a/Arf</italic>
###xml 223 227 223 227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003949-Chin1">[35]</xref>
###xml 403 407 403 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003949-Tief1">[36]</xref>
###xml 490 494 490 494 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003949-Chin1">[35]</xref>
###xml 496 500 496 500 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003949-Tief1">[36]</xref>
###xml 502 506 502 506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003949-Regales1">[37]</xref>
###xml 649 653 649 653 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003949-Chin1">[35]</xref>
###xml 382 387 <span type="species:ncbi:10090">mouse</span>
###xml 554 558 <span type="species:ncbi:10090">mice</span>
###xml 683 687 <span type="species:ncbi:10090">mice</span>
###xml 798 802 <span type="species:ncbi:10090">mice</span>
###xml 1053 1056 <span type="species:ncbi:10090">GEM</span>
Previously, we have engineered an inducible bitransgenic HRASV12-driven melanoma model possessing both activator (Tyr-rtTA) and reporter (Tet-HRASV12) transgenes on Ink4a/Arf-/- background (hereafter designated as "iHRAS*")[35]. The rtTA transgene was driven by a Tyrosinase enhancer-promoter element consisting of a 5 Kb upstream enhancer element fused to the proximal promoter of mouse tyrosinase gene[36]. This promoter has been used extensively as a melanocyte-specific promoter element[35], [36], [37]. To our surprise, while majority of the iHRAS* mice succumbed to invasive and angiogenic cutaneous melanomas in a doxycycline-dependent manner[35], a handful of the aging male mice that escaped the melanoma fate developed invasive prostate tumors (unpublished observations). Similarly, male mice from an identically engineered iNRAS* model also succumbed to prostate cancer if they did not develop melanoma (unpublished observations). These unanticipated observations suggest that prostate cancer is a late-onset tumor phenotype in RAS-activated GEM models engineered with this particular tyrosinase promoter-enhancer element. Furthermore, it raised the possibility that oncogenic alleles with weaker activity in melanocytes might favor more robust prostate cancer phenotype.
###end p 7
###begin p 8
###xml 346 351 346 351 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 424 428 424 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003949-Cho1">[25]</xref>
###xml 480 487 480 487 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 56 60 <span type="species:ncbi:10090">mice</span>
###xml 402 407 <span type="species:ncbi:9606">human</span>
Indeed, when we constructed an iBRAF* model, the iBRAF* mice were minimally melanoma-prone (data not shown). Instead the iBRAF* transgenic males were highly susceptible to the development of aggressive prostate neoplasms in a doxycycline-dependent manner. Since activated BRAF is one of the most potent activators of MAP kinase signaling and BRAFV600E mutation itself has been described in a subset of human prostate cancers[25], this iBRAF* model represents a potentially useful in vivo system in which to address the role of MAP kinase activation in prostate cancer genesis and progression.
###end p 8
###begin title 9
Results
###end title 9
###begin title 10
BRAF* activation drives aberrant proliferation in p63+ basal epithelial cells of the prostate
###end title 10
###begin p 11
###xml 327 328 327 328 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*</sup>
###xml 309 342 309 342 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Tyr-rtTA::Tet-BRAF<sup>*</sup>::Ink4a/Arf&#8722;/&#8722;</italic>
###xml 358 362 358 362 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 569 578 569 578 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003949-g001">Figure 1A</xref>
###xml 604 625 604 625 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in situ hybridization</italic>
###xml 665 669 665 669 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 684 689 684 689 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF*</italic>
###xml 776 781 776 781 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF*</italic>
###xml 796 800 796 800 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rtTA</italic>
###xml 807 809 807 809 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">nb</italic>
###xml 812 816 812 816 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rtTA</italic>
###xml 1048 1053 1048 1053 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF*</italic>
###xml 1080 1084 1080 1084 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rtTA</italic>
###xml 1232 1241 1232 1241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003949-g001">Figure 1B</xref>
###xml 1279 1315 1279 1315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003949-g001">Figure 1B, zoom-in panel, see arrows</xref>
###xml 1508 1512 1508 1512 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rtTA</italic>
###xml 1523 1542 1523 1542 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Materials &amp; Methods</xref>
###xml 1610 1619 1610 1619 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003949-g001">Figure 1C</xref>
###xml 1630 1634 1630 1634 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rtTA</italic>
###xml 1760 1764 1760 1764 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rtTA</italic>
###xml 74 89 <span type="species:ncbi:10090">transgenic mice</span>
###xml 401 405 <span type="species:ncbi:10090">mice</span>
###xml 428 432 <span type="species:ncbi:10090">mice</span>
The occurrence of prostate cancers in tyrosinase promoter/enhancer-driven transgenic mice prompted a detailed analysis of transgene expression in the prostate. Examination of transgene expression was performed in all 3 lobes of the prostate glands in 8-week-old bi-transgenic iBRAF* males (iBRAF*, short for "Tyr-rtTA::Tet-BRAF*::Ink4a/Arf-/-"). We detected BRAF* transcripts in all 3 lobes of iBRAF* mice on doxycycline (n = 2 mice examined), but not in whole prostate glands derived from WT or iBRAF* transgenic males off doxycycline using transgene-specific RT-PCR (Figure 1A; n = 2 for each). As RNA in situ hybridization (RISH) of BRAF detects both endogenous BRAF and transgene BRAF* expression throughout the prostatic epithelium (data not shown), we tracked transgene BRAF* expression by rtTA RISH (nb., rtTA is foreign to the mammalian genome). Upon doxycycline exposure, rtTA is known to potently drive expression of a transgene linked to a Tet-responsive promoter and is therefore a highly specific read-out of the Tet-driven transgene (BRAF* in this case) expression. rtTA transcripts were not detected in non-transgenic wild-type prostate gland, yet were abundant in iBRAF* transgenic prostates exposed to doxycycline (Figure 1B), particularly in the luminal cells (Figure 1B, zoom-in panel, see arrows). To further refine localization of transgene expression in the epithelium and determine whether the transgene is also expressed in the basal cell compartment, we performed serial p63 IHC and rtTA RISH (see Materials & Methods) in 8-week-old male iBRAF* prostate glands induced on doxycycline (Figure 1C). Indeed, rtTA transcripts were found in both p63+ basal cells and luminal cells (approximately 50% of the p63+ basal cells showed stronger rtTA expression; see arrows), indicating that this transgenic system can target expression to both the basal progenitor and the luminal compartments of prostate glands.
###end p 11
###begin title 12
###xml 10 14 10 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
Transgene BRAF* expression in prostate epithelium drives aberrant proliferation of the p63+ prostatic basal cells.
###end title 12
###begin p 13
###xml 13 18 13 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF*</italic>
###xml 446 453 446 453 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in situ</italic>
###xml 521 526 521 526 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF*</italic>
###xml 608 612 608 612 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rtTA</italic>
###xml 703 708 703 708 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF*</italic>
###xml 1119 1123 1119 1123 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rtTA</italic>
###xml 1235 1239 1235 1239 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">rtTA</italic>
###xml 217 221 <span type="species:ncbi:10090">mice</span>
###xml 350 354 <span type="species:ncbi:10090">mice</span>
###xml 842 846 <span type="species:ncbi:10090">mice</span>
###xml 1694 1698 <span type="species:ncbi:10090">mice</span>
A. Transgene BRAF* transcript was detected in all three lobes (AP, anterior prostate; VP, ventral prostate; DLP, dorsolateral prostate) of the prostate glands from two independent 8-week-old bi-transgenic iBRAF* male mice on doxycycline by transgene-specific RT-PCR. As controls, whole prostate glands were isolated from WT or iBRAF* off doxycycline mice (n = 2 for each). Ribosomal protein R15 was used as an internal control for RT-PCR. B. RNA in situ hybridization (RISH) using rtTA riboprobe documented expression of BRAF* transgene in prostate epithelial gland (200x). Arrows indicate the expression of rtTA in luminal cell compartment in zoom-in with higher magnification (400x). C. Expression of BRAF* transgene was detected in both luminal cells and p63+ basal cells of the prostate epithelium of 8-week-old bi-transgenic iBRAF* male mice on doxycycline using dual serial staining of p63 IHC and rtTA RISH. After quick incubation of slides with antibody against p63 for 10 minutes with IHC procedure, RISH procedure with rtTA RNA probe was followed. Brown color for p63+ basal cells by IHC and purple color for rtTA expression by RISH were differentially detected by spectro-imaging machine. Note the co-localization of strong rtTA expression and p63 immuno-reactivity in approximately 50% of p63+ basal cells (arrows). D. Ki67 staining of histologically-normal prostate glands in 8-week-old males showed increased proliferation index in iBRAF* transgenic (on doxycycline) compared to WT. E. Co-immunofluorescence study in prostate glands isolated from 8-week-old WT and iBRAF* transgenic (on doxycycline) males showed the expansion of p63+ basal cells in the prostate glands of iBRAF* mice. Approximately half of the p63+ cells were in proliferation as measured by co-staining with Ki67 (see arrows).
###end p 13
###begin p 14
###xml 36 41 36 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF*</italic>
###xml 476 485 476 485 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003949-g001">Figure 1D</xref>
###xml 694 703 694 703 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003949-g001">Figure 1E</xref>
###xml 196 200 <span type="species:ncbi:10090">mice</span>
To examine the functional impact of BRAF* transgene expression in the prostate, we monitored doxycycline-dependent proliferative responses in histologically normal prostates of iBRAF* and control mice. These analyses revealed enhanced epithelial proliferation documented by increased Ki67 index from 2.25 (+/-0.83) per 100 nuclei in 8-week-old WT to 6.9 (+/-0.95) per 100 nuclei in age-matched iBRAF* prostate (n = 300 nuclei/areax5 areas counted in each sample; p = 0.00035; Figure 1D). Notably, this BRAF*-induced proliferative response was more prominent in the basal cell compartment, as evident by the observation that most of the strong Ki67 positive signals were confined to p63+ cells (Figure 1E; approximately 50% of p63+ basal cells in iBRAF* prostate glands were positive for Ki67).
###end p 14
###begin title 15
###xml 7 11 <span type="species:ncbi:10090">mice</span>
iBRAF* mice developed invasive adenocarcinoma of the prostate
###end title 15
###begin p 16
###xml 265 274 265 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003949-g002">Figure 2A</xref>
###xml 392 401 392 401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003949-g001">Figure 1E</xref>
###xml 477 486 477 486 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003949-g002">Figure 2A</xref>
###xml 565 574 565 574 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003949-g001">Figure 1E</xref>
###xml 658 667 658 667 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003949-g002">Figure 2A</xref>
###xml 1006 1015 1004 1013 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003949-g002">Figure 2B</xref>
###xml 1028 1036 1026 1034 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0003949.s001">Table S1</xref>
###xml 1143 1167 1141 1165 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Tet-B-RAF*::Ink4a/Arf&#8722;/&#8722;</italic>
###xml 1226 1234 1224 1232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0003949.s001">Table S1</xref>
###xml 1418 1426 1414 1422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0003949.s001">Table S1</xref>
###xml 1443 1447 1439 1443 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">BRAF</italic>
###xml 1541 1550 1537 1546 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0003949.s002">Figure S1</xref>
###xml 455 459 <span type="species:ncbi:10090">mice</span>
###xml 749 753 <span type="species:ncbi:10090">mice</span>
###xml 1065 1069 <span type="species:ncbi:10090">mice</span>
###xml 1132 1136 <span type="species:ncbi:10090">mice</span>
A serial histopathological examination of the prostates from iBRAF* transgenic males was conducted to assess the long-term consequences of sustained BRAF* expression in the prostate epithelium. After 5 weeks of iBRAF* induction in 8-week-old animals (left panel in Figure 2A), the prostate gland appeared largely normal although moderate degree of aberrant proliferation was already evident (Figure 1E). Basaloid hyperplasia became evident in 16-week-old mice (middle panel in Figure 2A), consistent with prominent proliferative responses in the basal compartment (Figure 1E), followed by emergency of frank adenocarcinoma by 24 weeks of age (right panel in Figure 2A). Careful follow-up and characterization of a large colony of iBRAF* and control mice showed that only iBRAF* males on doxycycline were prone to PCA development with high penetrance. In founder line #29, 21/34 bi-transgenic iBRAF* males on doxycycline (ON) developed prostate tumors with an average latency of 24 weeks (SD = +/-6 weeks) (Figure 2B, Supporting Table S1). In comparison, all iBRAF* mice off doxycycline (OFF, n = 10) and single transgenic Tet-BRAF* mice (e.g. Tet-B-RAF*::Ink4a/Arf-/-) on doxycycline (ON, n = 9) remained PCA free (Supporting Table S1). Similar observations were made in a smaller cohort derived from founder line #13 where 3/10 doxycyline-treated iBRAF* males developed PCA with a latency of 23+/-6 weeks (Supporting Table S1). Additionally, BRAF* transgene expression could be documented in these PCA tumors by RT-PCR and RISH (Supporting Figure S1; data not shown for RISH).
###end p 16
###begin title 17
iBRAF* transgenic males develop invasive adenocarcinoma of the prostate.
###end title 17
###begin p 18
###xml 69 84 <span type="species:ncbi:10090">transgenic mice</span>
###xml 195 200 <span type="species:ncbi:10090">mouse</span>
###xml 271 286 <span type="species:ncbi:10090">transgenic mice</span>
###xml 504 508 <span type="species:ncbi:10090">mice</span>
###xml 702 707 <span type="species:ncbi:10090">mouse</span>
###xml 980 984 <span type="species:ncbi:10090">mice</span>
###xml 1035 1040 <span type="species:ncbi:10090">mouse</span>
###xml 1300 1305 <span type="species:ncbi:10090">mouse</span>
A. Time-course histological analysis of prostate samples from iBRAF* transgenic mice (on doxycycline) at the indicated ages. Hyperplastic lesions were detected in a 16-week-old iBRAF* transgenic mouse on doxycycline. Up to an age of 24 weeks, approximately 50% of iBRAF* transgenic mice developed PCA. B. Kaplan-Meier analysis of PCA-free survival in iBRAF* (on doxycycline, n = 34), iBRAF* (off doxycycline, n = 9), and Tet-BRAF* (on doxycycline, n = 10) transgenic males. Only double transgenic iBRAF* mice given doxycycline in their drinking water developed PCA with an average latency of 24 weeks (standard deviation = +/-6 weeks). C. Gross morphology of a prostate tumor from an iBRAF* transgenic mouse. T indicates tumor; B, bladder; and Te, testis. D. The transition from ductal (arrowhead) to spindle (asterisk) morphology is coincident with loss of E-cadherin expression in iBRAF* PCA, consistent with EMT (epithelial-mesenchymal transition). E. Detection of PCA in live mice by MRI. Panel a is a representative image of a WT mouse with normal prostate (highlighted in blue). Panel b is a representative MR image of PCA in an iBRAF* male on doxycycline (red outline; note heterogeneous signals within the lesion). Panel c is a representative MR image of hydronephrosis detected in an iBRAF* mouse with PCA. Note enlarged distended kidney (yellow arrow) in contrast to normal kidney in panel b (green arrow), indicating accumulation of urine in the kidney due to outflow obstruction by the tumor.
###end p 18
###begin p 19
###xml 91 100 91 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003949-g002">Figure 2C</xref>
###xml 320 356 320 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003949-g002">Figure 2D, compare asterisk to arrow</xref>
###xml 506 533 506 533 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003949-g002">Figure 2E-b, dashed outline</xref>
###xml 754 778 754 778 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003949-g002">Figure 2E-c yellow arrow</xref>
###xml 612 617 <span type="species:ncbi:9606">human</span>
###xml 618 626 <span type="species:ncbi:9606">patients</span>
iBRAF* PCA tumors were rapidly growing, reaching large size and causing local obstruction (Figure 2C). Consistent with its aggressive nature, iBRAF* tumors exhibited epithelial-mesenchymal transition (EMT) associated with downregulation of E-cadherin at the transition from ductal to spindle morphology in these tumors (Figure 2D, compare asterisk to arrow). By high-spatial resolution MRI, PCA could be readily discerned by the appearance of an enlarged, heterogeneous mass often compressing the bladder (Figure 2E-b, dashed outline; see panel E-a for normal prostate size marked by blue highlight). As in some human patients, these large lesions caused bladder outlet obstruction and hydronephrosis-distention of the kidney due to outflow obstruction (Figure 2E-c yellow arrow).
###end p 19
###begin p 20
###xml 411 422 411 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003949-g005">Figure 5A,B</xref>
###xml 465 469 465 469 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 567 576 567 576 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003949-g005">Figure 5A</xref>
###xml 755 764 755 764 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003949-g005">Figure 5C</xref>
###xml 850 859 850 859 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ink4a/Arf</italic>
The complex and context-specific interactions between RAS and PI3K signaling components coupled with the well-documented prominence of PI3K-PTEN-AKT aberrations in PCA prompted analysis of downstream signaling events in a collection of iBRAF* PCA tumors. Consistent with the known ability to BRAF* to potently activate MAPK signaling, all iBRAF* tumors showed p-ERK activation by Western blot and IHC analyses (Figure 5A,B). Notably, while Western blot analysis of Pten-null PCA showed strong AKT activation, none of the iBRAF* tumors examined showed AKT activation (Figure 5A). IHC analysis of additional iBRAF* prostate tumors (n = 17) mirrored these Western blot results, showing absence of AKT activation and readily detectable p-S6 immunoreactivity (Figure 5C). Thus, activated BRAF* expression targeted to prostate epithelium in the context of Ink4a/Arf deficiency triggers a proliferative response in the basal p63+ compartment, which when sustained, progresses with high penetrance to basaloid hyperplasia and ultimately invasive adenocarcinoma, without evidence for concomitant AKT activation.
###end p 20
###begin title 21
iBRAF* prostate tumors are epithelial
###end title 21
###begin p 22
###xml 182 190 182 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003949-g003">Figure 3</xref>
###xml 366 369 366 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003949-AbateShen1">[8]</xref>
###xml 721 725 721 725 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003949-Hudson1">[38]</xref>
###xml 727 731 727 731 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003949-Verhagen1">[39]</xref>
###xml 875 879 875 879 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003949-Segawa1">[40]</xref>
###xml 892 901 892 901 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0003949.s003">Figure S2</xref>
Given the complex histopathological presentation of the tumors, we utilized a suite of validated prostate lineage markers to determine the origin of these iBRAF* tumors. As shown in Figure 3, androgen receptor (AR) and Nkx3.1 are expressed in both ductal and spindled components. Nkx3.1 is the earliest known differentiation marker of the prostate luminal epithelium[8], and interestingly its expression was significantly reduced or absent in the spindled cell region of the tumors, possibly reflecting a less differentiated state. Basal cell markers, cytokeratin (CK) 14 and p63 were strongly positive, especially in the ductal components, as was CK19, a marker for transit-amplifying or intermediate differentiated cell[38], [39]. This epithelial markers profile, coupled with negative immunoreactivity to chromogranin and synaptophysin, two markers of neuroendocrine cells[40] (Supporting Figure S2), indicates that iBRAF* PCA are epithelial tumors.
###end p 22
###begin title 23
iBRAF* prostate tumors exhibit epithelial lineage markers.
###end title 23
###begin p 24
Both ductal and spindled components of iBRAF* prostate tumors express epithelial lineage markers: CK14 and p63 for basal cell, AR and Nkx3.1 for luminal cell, and CK19 for transit-amplifying cells.
###end p 24
###begin p 25
###xml 139 143 139 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003949-Cunha1">[41]</xref>
###xml 261 270 261 270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003949-g004">Figure 4A</xref>
###xml 396 405 396 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003949-g004">Figure 4B</xref>
###xml 596 616 596 616 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003949-g004">Figure 4B left panel</xref>
###xml 696 717 696 717 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003949-g004">Figure 4B right panel</xref>
###xml 1022 1031 1022 1031 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003949-g004">Figure 4C</xref>
###xml 1190 1197 1190 1197 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">de novo</italic>
###xml 1270 1279 1270 1279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0003949.s004">Figure S3</xref>
###xml 1397 1406 1397 1406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0003949.s004">Figure S3</xref>
###xml 1590 1597 1590 1597 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">de novo</italic>
###xml 1615 1636 1615 1636 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003949-g005">Figure 5C right panel</xref>
###xml 1715 1722 1715 1722 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">de novo</italic>
###xml 1838 1843 1838 1843 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">iBRAF</italic>
###xml 202 206 <span type="species:ncbi:10090">mice</span>
###xml 247 251 <span type="species:ncbi:10090">mice</span>
###xml 255 259 <span type="species:ncbi:10116">rats</span>
###xml 341 345 <span type="species:ncbi:10090">mice</span>
###xml 457 460 <span type="species:ncbi:10116">rat</span>
###xml 540 549 <span type="species:ncbi:10090">nude mice</span>
###xml 1198 1213 <span type="species:ncbi:10090">transgenic mice</span>
###xml 1598 1613 <span type="species:ncbi:10090">transgenic mice</span>
To functionally document the epithelial nature of iBRAF* PCA, we utilized the tissue recombinant approach pioneered by Cunha and colleagues[41]. Here, recombinant of epithelium from iBRAF* or wild type mice was mixed with mesenchymal tissues from mice or rats (Figure 4A for design) then grafted under the kidney capsules of adult nude male mice. Grafts were harvested 6 weeks later. As shown in Figure 4B, Recomb A grafts (comprising iBRAF* epithelium and rat mesenchyme) were significantly larger than Recomb B grafts (the converse) from nude mice supplemented with doxycycline drinking water (Figure 4B left panel). On the other hand, without doxycycline, Recomb A grafts were normal in size (Figure 4B right panel). Histological analysis of these grafts confirmed basaloid hyperplasia and PIN in grafts from Recomb A ON doxycycline only, while Recomb B grafts from the same hosts or Recomb A from hosts without doxycycline showed normal glandular structure that was indistinguishable from the Recomb C and D controls (Figure 4C). These doxycyline-induced hyperplastic and PIN lesions from Recomb A ON doxycycline grafts exhibited similar marker profile as described for tumors from the de novo transgenic mice-positive for Nkx3.1, AR, CK19, CK14 and p63 (Supporting Figure S3; data not shown for CK19 and CK14) as well as evidence for significant expansion of the p63+ compartment (Supporting Figure S3). On the biochemical level, a profile of robust p-ERK and p-S6K activation without detectable p-AKT activity was observed in these tissue recombinant specimens similar to tumors from de novo transgenic mice (Figure 5C right panel and data not shown for p-ERK). In summary, lineage marker characterization of de novo transgenic tumors, coupled with the functional data in the tissue recombinant system, provides clear evidence that iBRAF* PCA are invasive adenocarcinomas expressing luminal, intermediate and basal cell markers.
###end p 25
###begin title 26
iBRAF* embryonic urogenital epithelium drives basaloid hyperplasia in the tissue recombination system.
###end title 26
###begin p 27
###xml 100 105 <span type="species:ncbi:10090">mouse</span>
###xml 121 124 <span type="species:ncbi:10116">rat</span>
###xml 201 210 <span type="species:ncbi:10090">nude mice</span>
###xml 257 262 <span type="species:ncbi:10090">mouse</span>
###xml 278 281 <span type="species:ncbi:10116">rat</span>
###xml 387 391 <span type="species:ncbi:10090">mice</span>
###xml 414 418 <span type="species:ncbi:10090">mice</span>
###xml 528 533 <span type="species:ncbi:10090">mouse</span>
###xml 549 552 <span type="species:ncbi:10116">rat</span>
A. Schematic representation of the tissue recombination protocol. Recombinants of iBRAF* transgenic mouse epithelium and rat mesenchyme (Recomb A) were grafted under the right kidney capsules of adult nude mice. The converse recombinants (iBRAF* transgenic mouse mesenchyme and rat epithelium; Recomb B) were also transplanted in the same manner into the left kidney capsule of the same mice. Three of the grafted mice were fed doxycycline drinking water, and two were not. As controls, recombinants of non-transgenic wild-type mouse epithelium and rat mesenchyme (Recomb C) and the converse recombinants (Recomb D) were grafted in the same manner. Grafts were harvested 6 weeks later. B. Macroscopic images show that grafts with Recomb A on doxycycline are larger than both grafts with Recomb B on doxycycline and grafts with Recomb A off doxycycline. C. Histological analysis of these tissue grafts confirmed basaloid hyperplasia only in grafts with Recomb A on doxycycline, while others showed normal histology.
###end p 27
###begin title 28
iBRAF* prostate tumors are AKT-independent.
###end title 28
###begin p 29
###xml 277 281 277 281 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 589 592 589 592 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Nkx</italic>
###xml 600 604 600 604 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pten</italic>
###xml 287 291 <span type="species:ncbi:10090">mice</span>
###xml 329 334 <span type="species:ncbi:10090">mouse</span>
###xml 458 463 <span type="species:ncbi:10090">mouse</span>
###xml 479 482 <span type="species:ncbi:10116">rat</span>
###xml 624 628 <span type="species:ncbi:10090">mice</span>
A, B. p-ERK activation in iBRAF* PCA tumors (n = 5; on doxycycline) was detected by immunoblotting analysis (A) and IHC (B). In contrast, p-AKT activation was not detected in all iBRAF* PCA tumors (n = 5; on doxycycline). Controls (a & b) were two prostate cancer samples from Pten-null mice and WT was prostate glands from a WT mouse. C. p-AKT immunoreactivity was not detected on iBRAF* PCA tumors (n = 17) and Recomb A (a recombinant of iBRAF* transgenic mouse epithelium and rat mesenchyme on doxycycline) by IHC, but strong immunoreactivity of p-S6 was still present. PCA sample from Nkx3.1-/-, Pten+/- compound mutant mice were used as control.
###end p 29
###begin title 30
iBRAF* PCA progress to indolent androgen-independent tumors after castration
###end title 30
###begin p 31
###xml 839 848 839 848 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003949-g006">Figure 6A</xref>
###xml 864 873 864 873 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0003949.s005">Figure S4</xref>
###xml 1106 1115 1106 1115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003949-g006">Figure 6B</xref>
###xml 1258 1267 1258 1267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003949-g006">Figure 6C</xref>
###xml 1589 1598 1589 1598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003949-g006">Figure 6C</xref>
###xml 86 91 <span type="species:ncbi:9606">human</span>
###xml 261 265 <span type="species:ncbi:10090">mice</span>
###xml 793 797 <span type="species:ncbi:10090">mice</span>
###xml 979 983 <span type="species:ncbi:10090">mice</span>
Emergence of androgen-independence represents the most significant disease process in human PCA from the standpoint of mortality, prompting us to determine whether the iBRAF* model develops androgen independent (AI) tumors. To this end, we identified 10 iBRAF* mice with documented PCA by MRI screening for heterogeneous mass in the prostate gland (representing PCA) for castration. Despite frequent bladder irrigation in an effort to relieve outlet obstruction, 50% (n = 5) animals succumbed peri-operatively which was likely due to a generally compromised physiological state secondary to renal failure. Of the surviving animals, two were sacrificed at one-week post-castration (#36 and #57) and the remaining 3 were followed by weekly MRI for 4 weeks. Volumes of the prostate mass in all 5 mice decreased during the observation period (Figure 6A and Supporting Figure S4) but histopathological examination identified residual tumor nodules in two of the five castrated iBRAF* mice (#46 and #57). These tumor nodules were AR+ and p63+ with strong p-ERK and p-S6K activation but without detectable p-AKT (Figure 6B). That they were comprised of viable malignant cells was shown by low apoptosis index, comparable with index observed in pre-castrated tumor (Figure 6C). However, compared to the rapidly growing pre-castration tumors, these post-castrated tumors were indolent, with proliferation indices of 6.8 (+/-3.6) and 6.2 (+/-2.2), respectively, compared to an index of 26.6 (+/-3.6) in the pre-castrated tumors (n = 300 nuclei/areax5 areas counted in each sample; p<0.001 for both; Figure 6C). Thus, it appears that BRAF driven ERK and S6K activation alone is not sufficient to drive androgen-independent growth post castration, although it appears to be permissive of survival in low androgen state.
###end p 31
###begin title 32
iBRAF* PCA progress to indolent androgen-independence after castration.
###end title 32
###begin p 33
###xml 400 404 <span type="species:ncbi:10090">mice</span>
A. The reduction of tumor volumes was monitored by MRI over a 4-week time course after castration (a, tumor (blue) 1 week after castration; b, tumor (green) 2 weeks after castration; c, tumor (yellow) 3 weeks after castration; d, tumor (orange) 4 weeks after castration). Asterisk indicates bladder. B. Histological examination confirmed the presence of prostatic tumor cells in two castrated iBRAF* mice (#46 and #57). The two post-castration tumors were positive for AR (a prostatic luminal cell marker) and p63 (a basal cell marker) by IHC. Also, the post-castration tumor cells were negative for p-AKT, but remained strongly positive for p-ERK and p-S6K on IHC. C. The post-castration tumor cells were viable and growing, not residual tumor remnants, as manifested by low apoptosis index (1.2 (+/-0.45) and 1.4 (+/-0.55) per 100 nuclei for #46 and #57, respectively) on TUNEL, comparable to pre-castration tumor (1.0 (+/-0.71)) (top), and active proliferation by Ki67 staining, albeit at rate much lower than that of pre-castration tumor (6.8 (+/-3.6) and 6.2 (+/-2.2) for #46 and #57, respectively and 26.6 (+/-3.6) in the pre-castrated tumors) (bottom).
###end p 33
###begin title 34
BRAF activation is not required for iBRAF* PCA maintenance
###end title 34
###begin p 35
###xml 430 439 430 439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003949-g007">Figure 7A</xref>
###xml 841 850 841 850 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003949-g007">Figure 7B</xref>
###xml 863 912 863 912 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003949-g007">Figure 7C, compare immunoreactivity to left panel</xref>
###xml 1037 1044 1037 1044 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 236 240 <span type="species:ncbi:10090">mice</span>
###xml 582 586 <span type="species:ncbi:10090">mice</span>
To determine whether constitutive BRAF* signaling is required for iBRAF* tumor maintenance, we performed doxycycline withdrawal study in iBRAF* transgenic animals with documented PCA by MRI or by physical examination. First, two iBRAF* mice were identified as tumor-bearing and enlisted into serial MRI after doxycycline was removed from the drinking water. Unexpectedly, tumors continued to grow in both animals as shown on MRI (Figure 7A), requiring termination and sacrifice of ZD839 at one week and ZD835 at 4 weeks post doxycycline withdrawal. Similarly, two additional iBRAF* mice with tumors by palpation were taken off doxycycline; close follow-up revealed continued tumor growth, requiring sacrifice at 2 weeks and 4 weeks, respectively (data not shown). These off-doxycycline tumors did not express BRAF* by Western blot analysis (Figure 7B) or by IHC (Figure 7C, compare immunoreactivity to left panel). Accordingly, ERK phosphorylation was undetectable in ZD839 and only patchy in ZD835. Consistent with its continued growth in vivo, robust Ki67 and minimal TUNEL staining was documented in these off-doxycycline tumors, similar to the profile of on-doxycycline iBRAF* PCA. Taken together, these observations indicate that, while sustained BRAF* activation in the prostate gland is sufficient to drive development of invasive prostate adenocarcinoma, it is not required for maintenance of established PCA.
###end p 35
###begin title 36
iBRAF* prostate tumors do not require BRAF activation for their tumor maintenance.
###end title 36
###begin p 37
A. Tumor size change was monitored by serial MRI imaging before (baseline; solid line) and after (indicated periods; dotted line) doxycycline withdrawal (7 days for ZD839 and 28 days for ZD835). Yellow line indicates tumor boundary. B. B-RAF expression and p-ERK activation were not detected by immunoblotting analysis in most of off doxycycline iBRAF* PCA tumors (n = 3), although one of the off doxycycline iBRAF* tumor samples (ZD835) showed weak p-ERK activation. C. Immunohistological examination using antibodies against B-RAF and p-ERK confirmed the repression of B-RAF* transgene repression during off doxycycline periods (7 days for ZD839 and 28 days for ZD835). However, the tumors were viable and still growing, as manifested by low apoptosis on TUNEL and active proliferation by Ki67 staining.
###end p 37
###begin title 38
Discussion
###end title 38
###begin p 39
###xml 83 87 83 87 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003949-Cho1">[25]</xref>
###xml 808 812 808 812 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003949-Ma1">[42]</xref>
###xml 838 843 838 843 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">V600E</sup>
###xml 1010 1019 1010 1019 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0003949.s007">Figure S6</xref>
###xml 1054 1059 1054 1059 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">iBRAF</italic>
###xml 62 67 <span type="species:ncbi:9606">human</span>
###xml 207 212 <span type="species:ncbi:9606">human</span>
###xml 276 281 <span type="species:ncbi:10090">mouse</span>
###xml 852 857 <span type="species:ncbi:9606">human</span>
###xml 1103 1108 <span type="species:ncbi:9606">human</span>
This study, together with recently reported BRAF mutations in human prostate tumors[25], demonstrates the pathogenetic relevance of MAP kinase activation in prostate tumorigenesis. By targeting BRAF V600E-a human-relevant mutation known to potently activate MAP kinase-to the mouse prostate epithelium, we show here that MAP kinase activation can drive aberration proliferation and basaloid hyperplasia, leading to emergence of invasive adenocarcinoma of the prostate gland with short latency and high penetrance without evidence of AKT activation. The profile of strong ERK and S6K activation in the absence of AKT in iBRAF* tumors is consistent with the model proposed by Pandolfi and colleagues, whereby constitutive ERK activation inhibits TSC complex and subsequent activation of mTOR and downstream S6K[42]. In a cohort of four BRAFV600E mutated human PCA with strong pERK and pS6K activation by IHC, weak to absent pAKT immunoreactivity was indeed observed in two (#S04-7014 and #S04-7989 in Supporting Figure S6), supporting the notion that this iBRAF* transgenic system is modeling a subset of human PCA.
###end p 39
###begin p 40
###xml 134 138 134 138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003949-Gao1">[26]</xref>
###xml 140 144 140 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003949-Uzgare1">[43]</xref>
###xml 450 455 450 455 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">iBRAF</italic>
###xml 582 589 582 589 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 723 728 723 728 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">iBRAF</italic>
###xml 929 934 929 934 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">iBRAF</italic>
###xml 1169 1176 1169 1176 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1207 1214 1207 1214 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ex-vivo</italic>
###xml 1233 1237 1233 1237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003949-Gao1">[26]</xref>
###xml 3 8 <span type="species:ncbi:10090">mouse</span>
###xml 13 18 <span type="species:ncbi:9606">human</span>
###xml 157 162 <span type="species:ncbi:10090">mouse</span>
In mouse and human systems, activation of both AKT and ERK signaling is commonly observed during the initiation and progression of PCA[26], [43]. Since most mouse prostate cancer models are driven by AKT-activation, independent contribution of MAPK activation to prostate tumorigenesis has been difficult to establish. Here, by demonstrating that evolution from benign hyperplasia to invasive prostate tumors without concomitant AKT activation, this iBRAF* model offers the first genetic proof that MAPK activation alone is sufficient for initiation and progression to invasive PCA in vivo. Additionally, the ability to enforce MAPK activation via mutant BRAF expression under an androgen-insensitive promoter renders this iBRAF* model an ideal system for genetic dissection of MAPK contribution independent of AKT during AI progression. In this regard, although they grow rapidly in androgen-rich conditions, these AKT-negative iBRAF* PCA undergo complete or significant regression upon castration. Those indolent lesions surviving castration remain pAKT negative, pointing to its dispensability for survival in low-androgen state but likely requirement for AI growth in vivo, in line with recent study in ex-vivo manipulated system[26]. In summary, we conclude that while it may be permissive for survival post castration, BRAF driven MAPK activation is not sufficient to drive active growth under an androgen-limited state.
###end p 40
###begin p 41
###xml 556 565 556 565 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0003949.s006">Figure S5</xref>
###xml 914 918 914 918 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003949-Ji1">[44]</xref>
Finally, while MAPK activation alone can initiate prostate tumorigenesis, continued mutant BRAF expression or downstream MAPK activation is not required for maintenance of established PCA. Genetic inactivation of BRAF* by doxycycline withdrawal in 4 BRAF*-driven tumors did not lead to tumor growth inhibition nor regression. Corroborating with this was an intriguing finding that pharmacological inhibition of MEK with CI-1040 in renal capsule grafts of iBRAF* tumors (n = 2) did not inhibit tumor growth despite extinction of pERK activities (Supporting Figure S5). Taken together, these observations indicate that continued expression of mutant BRAF or activation of MAPK is not required to sustain growth or maintain viability of established PCA. This contrasts with findings in BRAF*-driven lung adenocarcinoma model where BRAF* acts not only as an initiating oncogene but shown to be required for maintenance[44], highlighting the context/lineage specific role(s) of an oncogenic event in genesis, progression and maintenance.
###end p 41
###begin p 42
###xml 60 65 <span type="species:ncbi:10090">mouse</span>
In summary, we describe here a novel genetically engineered mouse model of invasive PCA driven by MAPK activation via inducible BRAF mutation under an androgen-insensitive promoter. This model serves as a unique system for dissecting contribution of MAPK, relative to AKT, in development, progression and treatment of PCA.
###end p 42
###begin title 43
Materials and Methods
###end title 43
###begin title 44
###xml 39 54 <span type="species:ncbi:10090">transgenic mice</span>
Generation of inducible BRAF* (iBRAF*) transgenic mice
###end title 44
###begin p 45
###xml 199 203 199 203 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E600</sup>
###xml 323 324 321 322 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*</sup>
###xml 339 340 337 338 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*</sup>
###xml 390 399 388 397 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Ink4a/Arf</italic>
###xml 457 458 455 456 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">*</sup>
###xml 847 851 845 849 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E600</sup>
###xml 886 890 884 888 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003949-Chin1">[35]</xref>
###xml 2 7 <span type="species:ncbi:9606">human</span>
###xml 405 409 <span type="species:ncbi:10090">mice</span>
###xml 422 427 <span type="species:ncbi:10090">mouse</span>
###xml 505 510 <span type="species:ncbi:10090">mouse</span>
A human wild-type BRAF cDNA was cloned into a pBKS plasmid with its expression under the control of a minimal promoter containing multimerized tet-operons. A constitutively active form of mutant BRAFE600 was generated from the pBSK plasmid using QuikChange(R) Site-Directed Mutagenesis Kit (Stratagene) (designated Tet-BRAF*). The Tet-BRAF* construct was injected into oocytes derived from Ink4a/Arf null mice. Transgenic mouse lines harboring the Tet- BRAF* elements were crossed with another transgenic mouse lines expressing the reverse tetracycline transactivator under the control of the tyrosinase promoter/enhancer elements (designated Tyr-rtTA) to produce cohorts of single (Tet-BRAF*) and double (designated iBRAF*, Tet-BRAF*; Tyr-rtTA) transgenic animals. Doxycycline-supplemental drinking water was administered to induce transgene BRAFE600 expression as previously described[35].
###end p 45
###begin p 46
All animal experiments were performed according to a protocol approved by the Institutional Animal Care and Use Committee (IACUC) at Harvard Medical School.
###end p 46
###begin title 47
Transplantation of tissue recombinants
###end title 47
###begin p 48
###xml 185 189 185 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003949-Cunha1">[41]</xref>
###xml 46 51 <span type="species:ncbi:10090">Mouse</span>
###xml 56 59 <span type="species:ncbi:10116">rat</span>
###xml 288 293 <span type="species:ncbi:10090">mouse</span>
###xml 333 336 <span type="species:ncbi:10116">rat</span>
###xml 376 381 <span type="species:ncbi:10090">mouse</span>
###xml 421 424 <span type="species:ncbi:10116">rat</span>
###xml 554 559 <span type="species:ncbi:10090">mouse</span>
A two-way tissue recombination was performed. Mouse and rat embryonic urogenital sinuses were obtained at 16.5 days post coitum (dpc) and 18.5 dpc, respectively, as described previously[41]. After treatment of trypsin, epithelium and mesenchyme were separated under the microscope. Next, mouse urogenital sinus epithelium (mUGE) and rat urogenital sinus mesenchyme (rUGM), or mouse urogenital sinus mesenchyme (mUGM) and rat urogenital sinus epithelium (rUGE), were combined. Tissue recombinants were grafted under the kidney capsules of adult male nude mouse host for 6 weeks (with doxycycline on or off). Upon harvesting the grafts, tissues were fixed in 10% formalin overnight, and processed for histology and immunostaining.
###end p 48
###begin title 49
Histology and immunohistochemistry
###end title 49
###begin p 50
###xml 145 149 145 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003949-Aguirre1">[45]</xref>
###xml 892 899 890 897 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In Situ</italic>
All the tissue samples were fixed in 10% formalin overnight and embedded in paraffin. Immunohistochemistry were performed as described previously[45]. For antigen retrieval, slides were heated in 0.01 M citrate buffer (pH 6.0) in the microwave four times at four minutes each time. The antibodies and dilutions are: BRAF, 1:250 (Santa Cruz); phospho-Erk, 1:250 (Cell Signaling); Androgen Receptor, 1:250 (ABR); Ki-67, 1:2000 (Novacastra); Cytokeratin-14, 1: 50 (Biogenex); p63, 1:600 (Santa Cruz); Chromogranin A, 1:4000 (Diasorin); Synaptophysin, 1:500 (Santa Cruz); phospho-p70 S6 kinase 1:250 (Cell Signaling); E-cadherin, 1:250 (transduction lab); phospho-AKT(Ser473), 1:100 (Cell Signaling); Nkx3.1, 1:6000 (kindly provided by Dr. Cory Abate-Shen); and Cytokeratin 19, 1:20 (kindly provided by Dr. Nabeel Bardeesy). Apoptotic cell death was detected using the ApopTag(R) Plus Peroxidase In Situ Apoptosis Detection Kit (Chemicon).
###end p 50
###begin title 51
RNA In-situ hybridization (RISH)
###end title 51
###begin p 52
###xml 684 685 678 679 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1347 1351 1311 1315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003949-Byers1">[46]</xref>
###xml 1353 1357 1317 1321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003949-Tholouli1">[47]</xref>
The 10% formalin-fixed, paraffin-embedded slides were used for in situ hybridization with DIG-labeled riboprobe. DIG-labeled RNA probes were synthesized from a pBKS plasmid containing a rtTA PCR product (500 bp) using either T7 (for sense probe) or T3 (for anti-sense probe) promoter by in vitro transcription system with DIG RNA Labeling Mix (Roche Molecular Biochemicals, Mannheim, Germany). After deparaffinization, slides were digested in proteinase K solution (50 ug/ml) for 10 minutes at 37degreesC. DIG-labeled rtTA RNA probes were diluted in hybridization buffer at the concentration of 1 ug/ml. 100 ul of the diluted RNA probes was added on each slide and covered by 24x40 mm2 coverslip. Slides were hybridized at 60degreesC overnight, and washed at 65degreesC for 15 minutes twice in 2x SSC buffer with gentle agitating. After the treatment of RNAse A (10 ug/ml) for 30 minutes at 37degreesC, the slides were washed for 10 minutes twice at room temperature (RT) in 2x SSC buffer and followed by additional washing for 30 minutes twice at 65degreesC in 0.2x SSC buffer with gentle agitation. The slides were washed in PBS for 15 minutes twice at RT and then incubated with anti-Digoxigenin antibody conjugated with alkaline phosphatase (1:2000, Roche) overnight at 4degreesC. Color was developed by dipping the slides in NTB/BCIP solution[46], [47] approximately for two to four hours in the dark.
###end p 52
###begin p 53
For the dual staining, first with immunohistochemical staining procedure, the quick incubation of the slides with antibody against p63 for 10 minutes was performed, and then followed by RNA in situ hybridization procedure with rtTA RNA probe as mentioned above.
###end p 53
###begin title 54
MRI methods
###end title 54
###begin p 55
Magnetic resonance imaging was performed on a 4.7 T on a Bruker imaging system (Pharmascan, Karlsruhe, Germany). Protocols included a Tri-plane and coronal proton density weighted localizer. Multi-slice T2-weighted imaging was performed in the coronal and axial planes utilizing the following parameters: Flip angle = 90degrees; Matrix size (256x256); TR = 2500 msec; TE = 44.6 ms; field of view (FOV) = 4.24x2.12 cm, slice thickness = 1.2 mm. T1-weighted imaging was performed in the coronal and axial planes following the administration of intraperitoneal Gd-DTPA utilizing the following parameters: Flip angle = 90degrees; Matrix size (256x256); TR = 700 msec.; TE = 14 msec.; field of view (FOV) = 4.24x2.12 cm, slice thickness = 1.2 mm. Tumor volumes were determined by region of interest (ROI) analysis of T1-weighted post Gd-DTPA enhanced images using robust image analysis software (Osirix(R)). The sum of the region of interests was multiplied by the slice thickness to obtain tumor volumes. Tumor volumes are reported in cubic centimeter (cc).
###end p 55
###begin title 56
Molecular analysis
###end title 56
###begin p 57
###xml 105 109 105 109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003949-Aguirre1">[45]</xref>
RNA was isolated from the prostate tumor samples, and reverse-transcribed to cDNA as described previously[45]. A RT-PCR primer pair for the detection of transgene-specific BRAF expression was as follows (210-bp fragment):
###end p 57
###begin p 58
###xml 13 38 13 38 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-TCTTCATGAAGACCTCACA-3&#8242;</named-content>
RTM-BRAF-5F: 5'-TCTTCATGAAGACCTCACA-3'
###end p 58
###begin p 59
###xml 13 39 13 39 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-ACTGTCCAGTCATCAATTCA-3&#8242;</named-content>
RTM-BRAF-5R: 5'-ACTGTCCAGTCATCAATTCA-3'
###end p 59
###begin p 60
PCR amplification condition was 95degreesC for 15 min followed by 95degreesC for 1 min, 62degreesC for 1 min, and 72degreesC for 1 min with 31 cycles. As an internal control for RT-PCR, ribosomal protein R15 expression was used.
###end p 60
###begin p 61
###xml 79 83 79 83 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003949-Aguirre1">[45]</xref>
For western blot analysis, tumor lysates were extracted as described previously[45]. Total 20 micrograms of lysate was run on 4-12% Bis-Tris NuPAGE (Invitrogen), transferred to PVDF membrane (Perkinelmer), and blotted using the following antibodies: p-ERK, 1:500 (Cell Signaling); phospho-S6 Kinase, 1:500 (Cell Signaling); and p-AKT(Ser473), 1:250 (Cell Signaling).
###end p 61
###begin title 62
Supporting Information
###end title 62
###begin p 63
(0.03 MB RTF)
###end p 63
###begin p 64
Click here for additional data file.
###end p 64
###begin p 65
###xml 131 135 <span type="species:ncbi:10090">mice</span>
BRAF* transgene expression is documented by transgene-specific RT-PCR with two independent prostate tumors of bi-transgenic iBRAF* mice on doxycycline.
###end p 65
###begin p 66
(1.37 MB TIF)
###end p 66
###begin p 67
Click here for additional data file.
###end p 67
###begin p 68
Both ductal and spindled components of iBRAF* prostate tumors were negative for neuroendocrine markers (chromogranin and synaptophysin) by IHC. For controls, pancreatic tissues were used.
###end p 68
###begin p 69
(1.37 MB TIF)
###end p 69
###begin p 70
Click here for additional data file.
###end p 70
###begin p 71
Grafts from recombinant study showed a profile of lineage marker that is identical to that of the de novo iBRAF* PCA tumors.
###end p 71
###begin p 72
(1.37 MB TIF)
###end p 72
###begin p 73
Click here for additional data file.
###end p 73
###begin p 74
###xml 132 137 <span type="species:ncbi:10090">mouse</span>
###xml 422 427 <span type="species:ncbi:10090">mouse</span>
iBRAF* tumors regress after castration. A. Representative consecutive multi-slice MRI images (1.2 mm thickness) of pelvis of iBRAF* mouse #46 at baseline imaging (pre-castration) showing heterogeneous signal intensity characteristic of tumor (blue highlight). B. Changes in prostate tumor volumes over time after castration (n = 5) were calculated based on ROI on serial MRI images. For comparison, serial imaging of a WT mouse was shown. Asterisks indicate two post-castration tumors containing prostatic tumor cells on histological examination.
###end p 74
###begin p 75
(1.37 MB TIF)
###end p 75
###begin p 76
Click here for additional data file.
###end p 76
###begin p 77
###xml 260 263 <span type="species:ncbi:10116">rat</span>
###xml 321 330 <span type="species:ncbi:10090">nude mice</span>
###xml 360 364 <span type="species:ncbi:10090">mice</span>
###xml 697 701 <span type="species:ncbi:10090">mice</span>
###xml 795 799 <span type="species:ncbi:10090">mice</span>
Activation of B-RAF pathway is not required for tumor progression and maintenance. A. Schematic representation of CI-1040 (a MEK inhibitor) treatment protocol using tissue recombination. Tissue recombinants were generated with iBRAF* prostate cancer cells and rat mesenchymal cells, implanted under the kidney capsule of nude mice, and grown for 2 months. The mice were orally treated with CI-1040 at 150 mg/kg body weight twice a day for two weeks. B. Gross morphology and graft weight after two-week treatment showed significantly increased graft size with CI-1040 treatment, compared to mock-treated control (p = 0.032). C. Histological analyses of grafts from mock-treated and CI-1040-treated mice confirmed prostate tumor development. Although decreased p-ERK staining with CI-1040-treated mice indicated the inhibition of B-RAF pathway, tumors were still proliferating, as manifested by strong positivity with Ki67 staining.
###end p 77
###begin p 78
(1.37 MB TIF)
###end p 78
###begin p 79
Click here for additional data file.
###end p 79
###begin p 80
###xml 58 63 <span type="species:ncbi:9606">human</span>
###xml 211 216 <span type="species:ncbi:9606">human</span>
Strong activation of p-ERK and p-S6K was also observed in human prostate tumors harboring BRAFV600E mutation (total 8 samples; n = 4 with WT BRAF and n = 4 with BRAFV600E mutation). Importantly, two of the four human prostate tumors harboring BRAFV600E mutation showed no activation (BRAF V600 #S04-7014) or very weak activation of p-AKT (BRAF V600 #S04-7989).
###end p 80
###begin p 81
(1.37 MB TIF)
###end p 81
###begin p 82
Click here for additional data file.
###end p 82
###begin p 83
We thank Dr. R.A. DePinho for critical reading of the manuscript and members of the laboratories for helpful discussion.
###end p 83
###begin title 84
References
###end title 84
###begin article-title 85
###xml 11 17 <span type="species:ncbi:10090">murine</span>
###xml 65 70 <span type="species:ncbi:9606">human</span>
Myc-driven murine prostate cancer shares molecular features with human prostate tumors.
###end article-title 85
###begin article-title 86
Heterogeneous tumor evolution initiated by loss of pRb function in a preclinical prostate cancer model.
###end article-title 86
###begin article-title 87
###xml 14 18 <span type="species:ncbi:10090">mice</span>
Nkx3.1 mutant mice recapitulate early stages of prostate carcinogenesis.
###end article-title 87
###begin article-title 88
Pten dose dictates cancer progression in the prostate.
###end article-title 88
###begin article-title 89
BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair.
###end article-title 89
###begin article-title 90
PTEN and GSK3beta: key regulators of progression to androgen-independent prostate cancer.
###end article-title 90
###begin article-title 91
Progression of prostate cancer by synergy of AKT with genotropic and nongenotropic actions of the androgen receptor.
###end article-title 91
###begin article-title 92
Molecular genetics of prostate cancer.
###end article-title 92
###begin article-title 93
Androgen receptors in prostate cancer.
###end article-title 93
###begin article-title 94
p53 is mutated in a subset of advanced-stage prostate cancers.
###end article-title 94
###begin article-title 95
Preoperative p53, bcl-2, CD44 and E-cadherin immunohistochemistry as predictors of biochemical relapse after radical prostatectomy.
###end article-title 95
###begin article-title 96
Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis.
###end article-title 96
###begin article-title 97
p53 mutations in prostate cancer bone metastases suggest that selected p53 mutants in the primary site define foci with metastatic potential.
###end article-title 97
###begin article-title 98
###xml 65 70 <span type="species:ncbi:9606">human</span>
p53 protein accumulation and gene mutation in the progression of human prostate carcinoma.
###end article-title 98
###begin article-title 99
p53 and bcl-2 immunohistochemistry in pretreatment prostate needle biopsies to predict recurrence of prostate cancer after radical prostatectomy.
###end article-title 99
###begin article-title 100
p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate.
###end article-title 100
###begin article-title 101
Activation of mitogen-activated protein kinase associated with prostate cancer progression.
###end article-title 101
###begin article-title 102
v-rasH expression confers hormone-independent in vitro growth to LNCaP prostate carcinoma cells.
###end article-title 102
###begin article-title 103
###xml 47 52 <span type="species:ncbi:9606">human</span>
High-throughput oncogene mutation profiling in human cancer.
###end article-title 103
###begin article-title 104
###xml 76 79 <span type="species:ncbi:9606">men</span>
Comparison of ras activation in prostate carcinoma in Japanese and American men.
###end article-title 104
###begin article-title 105
High glucose stimulates synthesis of fibronectin via a novel protein kinase C, Rap1b, and B-Raf signaling pathway.
###end article-title 105
###begin article-title 106
BRAF point mutations in primary melanoma show different prevalences by subtype.
###end article-title 106
###begin article-title 107
Mutations of ras genes are relatively frequent in Japanese prostate cancers: pointing to genetic differences between populations.
###end article-title 107
###begin article-title 108
State of adenomatous polyposis coli gene and ras oncogenes in Japanese prostate cancer.
###end article-title 108
###begin article-title 109
BRAF and KRAS mutations in prostatic adenocarcinoma.
###end article-title 109
###begin article-title 110
###xml 61 66 <span type="species:ncbi:10090">mouse</span>
Combinatorial activities of Akt and B-Raf/Erk signaling in a mouse model of androgen-independent prostate cancer.
###end article-title 110
###begin article-title 111
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.
###end article-title 111
###begin article-title 112
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
Mouse models of prostate carcinogenesis.
###end article-title 112
###begin article-title 113
###xml 33 38 <span type="species:ncbi:10090">mouse</span>
Survey of genetically engineered mouse models for prostate cancer: analyzing the molecular basis of prostate cancer development, progression, and metastasis.
###end article-title 113
###begin article-title 114
###xml 71 76 <span type="species:ncbi:10090">mouse</span>
Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse.
###end article-title 114
###begin article-title 115
###xml 45 50 <span type="species:ncbi:10090">mouse</span>
A critical role for p27kip1 gene dosage in a mouse model of prostate carcinogenesis.
###end article-title 115
###begin article-title 116
Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model.
###end article-title 116
###begin article-title 117
###xml 11 16 <span type="species:ncbi:10090">mouse</span>
Transgenic mouse models for prostate cancer. Identification of an androgen-dependent promoter and creation and characterization of the long probasin promoter-Large T antigen (LPB-Tag) model.
###end article-title 117
###begin article-title 118
Serum- and glucocorticoid-inducible kinase SGK phosphorylates and negatively regulates B-Raf.
###end article-title 118
###begin article-title 119
Essential role for oncogenic Ras in tumour maintenance.
###end article-title 119
###begin article-title 120
###xml 41 56 <span type="species:ncbi:10090">transgenic mice</span>
Regulation of the tyrosinase promoter in transgenic mice: expression of a tyrosinase-lacZ fusion gene in embryonic and adult brain.
###end article-title 120
###begin article-title 121
###xml 85 90 <span type="species:ncbi:9606">human</span>
###xml 153 158 <span type="species:ncbi:10090">mouse</span>
Identification and functional validation of a 5' upstream regulatory sequence in the human tyrosinase gene homologous to the locus control region of the mouse tyrosinase gene.
###end article-title 121
###begin article-title 122
###xml 25 30 <span type="species:ncbi:9606">human</span>
Epithelial stem cells in human prostate growth and disease.
###end article-title 122
###begin article-title 123
###xml 62 67 <span type="species:ncbi:9606">human</span>
Colocalization of basal and luminal cell-type cytokeratins in human prostate cancer.
###end article-title 123
###begin article-title 124
Prognostic significance of neuroendocrine differentiation, proliferation activity and androgen receptor expression in prostate cancer.
###end article-title 124
###begin article-title 125
The endocrinology and developmental biology of the prostate.
###end article-title 125
###begin article-title 126
###xml 149 154 <span type="species:ncbi:9606">human</span>
Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase mediated mTOR activation in tuberous sclerosis and human cancer.
###end article-title 126
###begin article-title 127
Enhanced redundancy in Akt and mitogen-activated protein kinase-induced survival of malignant versus normal prostate epithelial cells.
###end article-title 127
###begin article-title 128
###xml 113 118 <span type="species:ncbi:10090">mouse</span>
Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models.
###end article-title 128
###begin article-title 129
Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma.
###end article-title 129
###begin article-title 130
Semiautomated multiplexed quantum dot-based in situ hybridization and spectral deconvolution.
###end article-title 130
###begin article-title 131
Imaging of multiple mRNA targets using quantum dot based in situ hybridization and spectral deconvolution in clinical biopsies.
###end article-title 131
###begin p 132
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 132
###begin p 133
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: J.H. Jeong and I. Guney are supported by Department of Defense (DOD) Prostate Cancer Training Awards. M.F. Loda is supported by NIH PO1 CA089021, Prostate Cancer Foundation (PCF) Award and DFCI-Novartis Investigator award. W.C. Hahn is supported by NIH RO1 CA109038 and the Prostate Cancer Foundation (PCF) Award. C. Abate-Shen is supported by NIH RO1 CA076501 and UO1 CA084294. R. Weissleder and all imaging studies are supported by NIH R24 CA92782, P50 CA86355, and U54 CA119349. This work is supported by grants from the NIH (UO1 CA84313; RO1 CA93947) to L. Chin. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 133

